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The connection between gut microbiota and energy homeostasis and inflammation and its role
in the pathogenesis of obesity-related disorders are increasingly recognized. Animals models of
obesity connect an altered microbiota composition to the development of obesity, insulin resis-
tance, and diabetes in the host through several mechanisms: increased energy harvest from the
diet, altered fatty acidmetabolism and composition in adipose tissue and liver, modulation of gut
peptide YY and glucagon-like peptide (GLP)-1 secretion, activation of the lipopolysaccharide
toll-like receptor-4 axis, andmodulation of intestinal barrier integrity byGLP-2. Instrumental for
gut microbiota manipulation is the understanding of mechanisms regulating gut microbiota
composition. Several factors shape the gut microflora during infancy: mode of delivery, type of
infant feeding, hospitalization, and prematurity. Furthermore, the key importance of antibiotic
use and dietary nutrient composition are increasingly recognized. The role of theWestern diet in
promoting an obesogenic gut microbiota is being confirmation in subjects. Following encour-
aging results in animals, several short-term randomized controlled trials showed the benefit of
prebiotics and probiotics on insulin sensitivity, inflammatory markers, postprandial incretins,
and glucose tolerance. Future research is needed to unravel the hormonal, immunomodulatory,
and metabolic mechanisms underlying microbe-microbe and microbiota-host interactions and
the specific genes that determine the health benefit derived from probiotics. While awaiting
further randomized trials assessing long-term safety and benefits on clinical end points, a healthy
lifestyle—including breast lactation, appropriate antibiotic use, and the avoidance of excessive
dietary fat intake—may ensure a friendly gut microbiota and positively affect prevention and
treatment of metabolic disorders.
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A long with the increasing worldwideincidence of obesity-associated dis-orders, research has recently unrav-
eled important pathways reciprocally
connecting metabolism with the immune
system. The development of obesity is a
complex process involving genetic sus-
ceptibility and environmental factors,
which both remain only partially under-
stood. In such instances, gutmicrobiota is
being increasingly recognized as an im-
portant factor connecting genes, environ-
ment, and immune system. The human
gut hosts an enormous number and vari-
ety of microorganisms, including at least
1014 bacteria belonging to 1,000 spe-
cies (1). The genome size of this microbial
organ, collectively named microbiome,
exceeds the size of the human nuclear ge-
nome by two orders of magnitude and
provides important biological and meta-
bolic functions that cannot be performed
by researchers. Genomic and environ-
mental factors at the basis of mutual host-
microbiota interactions have been
intensely investigated with metagenomic
and metabolomic approaches in the last 5
years. This article will discuss recent ad-
vances in understanding the role of gut
microbiota in the pathogenesis of obesity,
insulin resistance (IR), and diabetes and
their potential therapeutic applications.
Evidence for the role of gut
microbiota in the regulation of
energy homeostasis and fat storage
The first definite evidence for the role of
the gut microbiota in the regulation of
host energy homeostasis and adiposity
came from Gordon and colleagues’ (2)
group experiments: they noticed that
germ-free mice (i.e., raised in the absence
ofmicroorganisms) had40% less total body
fat than conventionally raised mice, even if
their caloric intake was 29% higher than
that of conventionally raised animals (sup-
plementary Table 1, available in the online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0556/DC1). In 2
weeks, conventionalization (i.e., coloniza-
tion of their gut with a cecum-derived,
distal microbial community) of germ-free
mice produced a 57% increase in total
body fat, a 2.3-fold increase in hepatic
triglycerides, and a dramatic increase in
IR without affecting chow consumption
or energy expenditure (2).
In a further key experiment, Backhed
et al. (3) fed germ-free or conventional-
ized mice a high-fat, high-carbohydrate
Western diet. After 8 weeks, germ-free
mice gained significantly less weight and
fat mass than conventionalized mice and
were protected against the Western diet-
induced glucose intolerance and IR. In
contrast to the previous experiment,
germ-free and conventionalized mice had
similar energy content in their feces, sug-
gesting a more efficient energy harvest
from the diet might not be the only factor
responsible for the fat mass gain of the
conventionalized mice. The investigators
also provided a mechanistic basis for the
observed resistance of germ-free mice to
diet-induced obesity (3):
1) conventionalization doubled the
density of small intestinal villi capillaries
and enhanced monosaccharide uptake
from the gut into the portal blood, stim-
ulated carbohydrate response element
binding protein-mediated and sterol re-
sponsive element binding protein-1–
mediated hepatic and adipose tissue
lipogenesis, eventually promoting fat ac-
cumulation in the liver and adipose
tissue.
2) gut microbiota-promoted storage
of circulating triglycerides into adipocytes
by suppressing intestinal secretion of an
inhibitor of adipose tissue lipoprotein
lipase called fasting-induced adipose
factor (FIAF), also known as angiopoi-
etin-like protein 4. Consistently, conven-
tionalization of FIAF-deficient knockout
(KO) mice produced only a 10% increase
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in total body fat compared with the 57%
fat gain observed in wild-type littermates;
germ-free FIAF KO mice fed a high-fat,
high-carbohydrate diet were not pro-
tected from diet-induced obesity (3).
Therefore, the blunted FIAF expression
might have contributed to triglyceride ac-
cumulation in adipocytes and adipose tis-
sue hypertrophy of conventionalized
germ-free mice.
3) germ-free mice showed an en-
hanced activation of hepatic and muscle
fatty acid oxidative pathways, which was
mediated by two complementary and in-
dependent mechanisms: a) an increased
activity of the enzymeAMP-activated pro-
tein kinase, which activates key enzymes
of mitochondrial fatty acid oxidation, in-
cluding acetyl-CoA carboxylase and car-
nitinepalmitoyltransferase I and b) an
increased FIAF-induced expression of the
nuclear transcription factor peroxisomal
proliferator-activated receptor coactiva-
tor-1, a key coactivator of nuclear recep-
tors and enzymes involved in fatty acid
oxidation.
Subsequent independent met-
agenomic and metabolomic studies pro-
vided further mechanistic insight into the
increased capacity of the obese gut micro-
biome to harvest energy from the diet:
1) the obese gut microbiome is de-
pleted of genes involved in motility (che-
motaxins, motility proteins, flagellar
assembly) and enriched in glycoside hy-
drolases, capable of breaking down
otherwise indigestible alimentary poly-
saccharides; in phosphotransferases in-
volved in the import of simple sugars
including glucose, fructose, andN-acetyl-
galactosamine; in -fructosidase, capable
of degrading fructose-containing carbo-
hydrates such as sucrose to lactate, bu-
tyrate, or acetate; and in other transport
proteins and fermentation enzymes fur-
ther processing breakdown products
(4,5).
2) gut microbiota on a high-fat diet
may convert dietary choline into hepato-
toxic methylamines, reducing choline
bioavailability of choline, which is neces-
sary for the assembly and secretion of
VLDLs and eventually promoting hepatic
steatosis, IR, and lipoperoxidation (6).
3) multicompartmental top-down
metabolic profiling revealed gut micro-
biota may modulate host hepatic and
systemic lipid metabolism through mod-
ification of bile acid conjugative patterns,
directly impacting on emulsification and
absorption properties of bile acids and in-
directly impacting on hepatic fat storage
and lipoperoxidation through bile acid
signaling properties (7).
Collectively, these experiments dem-
onstrated that gut microbiota may modu-
late both sides of the energy balance
equation, namely energy harvest from the
diet, energy storage as triglyceride, and
energy expenditure through fatty acid ox-
idation, and that may mediate diet-
induced obesity, IR, and diabetes.
Altered gut microbiota composition
in obesity: animal and human data
The human gut contains1,000 different
bacterial species with 99% of the total
population belonging to about 40 species
(1). The bacterial density progressively
increases along the small bowel from
104 in the jejunum to 107 colony-
forming units per gram of luminal content
at the ileal end, with a predominance of
gram-negative aerobes and some obligate
anaerobes (8). In the colon, the bacterial
count reaches around 1012 colony-
forming units per gram with a predomi-
nance of anaerobes. It has been estimated
that 60%of the fecalmass is accounted for
by bacteria (8). Despite these observa-
tions, research in the field has long been
hampered by methodological limitations.
Conventional culturing techniques can in
fact detect only30% of the total intesti-
nal bacteria (8) for several reasons: the
unknown growth requirements of the
bacteria, the selectivity of the media that
are used, the stress imposed by the culti-
vation procedures, the necessity of strictly
anoxic conditions, and the difficulties
with simulating the interactions of bacte-
ria with other microbes and host cells (8).
Recent culture-independent molecular
biologic approaches based on the se-
quence diversity of the small subunit
rRNA (16S rRNA and18S rRNA) gene
have overcome these limitations. Finger-
printing techniques, PCR and dot blot
hybridization, fluorescent in situ hybrid-
ization (FISH), and DNA microarrays
substantially enhanced the detection ca-
pability of numbers and the diversity of
human gut microbiota (9). Although con-
sistently magnifying the insight of inves-
tigators into microbial diversity, these
techniques each have their own biases
and limitations, which should be taken
into account when interpreting discrep-
ant results across studies. For instance,
FISH depends by its nature on sequence
data availability and hence, it fails to de-
tect novel RNA sequences. Furthermore,
FISH canmiss up to 30% of bacterial cells
in a given sample due to either cell per-
meability or probe mismatch issues (10).
Overall, the application of these mo-
lecular techniques revealed that species
inhabiting the human gastrointestinal
tract are dominated by anaerobic bacteria
and belong to three bacterial phyla (divi-
sions): the gram-positive Firmicutes and
Actinobacteria and the gram-negative
Bacteroidetes. The Firmicutes is the larg-
est bacterial phylum, comprising over
200 genera, including Lactobacillus,Myco-
plasma, Bacillus, and Clostridium species.
The Bacteroidetes (including 20 gen-
era) and the Actinobacteria also belong to
the dominant gut microbiota, but the lat-
ter are frequently missed by RNA gene
sequencing and can only be detected by
FISH (8). To further complicate this
picture, the prevalence and diversity of
bacteria in different areas of the gastroin-
testinal tract is influenced by the different
conditions at these sites and thus, the mi-
crobiota of the stomach and jejunum var-
ies with that of the large intestine.
Animal models suggest obesity is as-
sociated with alterations of the composi-
tion and the functional properties of the
gut microbiota, e.g., the development of
obesity in leptin-deficient ob/ob mice cor-
relates with a shift in the abundance of the
two dominating divisions, Bacteroidetes
and Firmicutes. Compared with lean lit-
termates fed the same polysaccharide-
rich diet, obesity was associated with a
50% reduction in Bacteroidetes and a
proportional division-wide increase in
Firmicutes (11).
The relationship between diet, gut
microbiota, and energy homeostasis was
further investigated in models of diet-
induced obesity (4,5), e.g., themicrobiota
ofmice fed a high-fat, high-sugarWestern
diet was compared with the microbiota of
mice receiving a low-fat, high-polysac-
charide diet. The Western diet increased
the relative abundance of Firmicutes due
to a bloom in the class of Mollicutes at the
expense of the Bacteriodetes, inducing
an enrichment in genes enabling energy
harvest from the diet (see above). Im-
portantly, these changes in microbial
composition and its functional properties
were totally reversed after a shift back to
the original diet (supplementary Table 1).
To further assess whether diet by itself can
affect gut microbiota composition inde-
pendent of obesity, Hildebrandt et al. (12)
employed the resistin-like molecule-
(RELM-) KO mice, a model that is resis-
tant to high-fat–induced obesity. When
RELM- KO and RELM-wild-type mice
Gut microbiota and obesity
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were switched from a standard diet to a
high-fat diet, the changes in the composi-
tion and functional properties of the gut
microbiome were similar between wild-
type and KO mice, indicating that the ef-
fects of diet dominated over the obese
phenotype.
To definitely demonstrate that altered
gutmicrobiota composition is a cause and
not a consequence of obesity or altered
dietary habits, caecal microbiota from
lean and obesemicewas transplanted into
the gut of germ-free mice. After 2 weeks,
the mice hosting the “obese microbiota”
extracted more calories from their food
and showed a significantly greater in-
crease in their fat mass than the mice col-
onized with the “lean gut microbiota”
(4,13). These data were independently
replicated by other models where the col-
onization of lean mice by gut microflora
extracted fromobese animals induced sig-
nificant fat gain and IR compared with the
microbiota extracted from lean animals
despite a similar caloric intake (4,5).
Data from human studies were gener-
ally consistent with the results from ani-
mal models, e.g., 12 obese subjects had
lower Bacteroidetes and more Firmicutes
in their distal gut than did lean control
subjects. After randomization to either
carbohydrate-restricted or fat-restricted
diets for 52 weeks, the proportion of Bac-
teroidetes increased over time, mirroring
reductions in host weight but not dietary
changes (14).
A subsequent metagenomic study
(15) with 154 individuals—including
monozygotic and dizygotic twins concor-
dant for leanness or obesity and their
mothers—also showed that obesity was
associated with a markedly reduced bac-
terial diversity, a relative depletion of Bac-
teroidetes, and a higher proportion of
Actinobacteria compared with leanness.
This large-scale study revealed that the
human gut microbiome is shared to some
extent among family members, but that
each person’s gut microbial community
varies in the specific bacterial lineages
present with a comparable degree of co-
variation between adult monozygotic and
dizygotic twin pairs. It also suggested the
gut microbiota is inherited to a significant
extent from the mothers, and that “inher-
itance” of the gut microbiota may bemore
important for microbial community
structure and function than the actual ge-
netic context of the host. Examined indi-
viduals notably shared a wide array of
microbial genes, named a “core gut mi-
crobiome” at the gene rather than at the
organismal level, comprising an enrich-
ment in phosphotransferases and other
carbohydrate-processing and lipid-
utilizing genes previously demonstrated
in animal models of diet-induced obesity.
Other relatively small studies exam-
ined gut microbiota composition in hu-
man obesity and type 2 diabetes and the
impact of weight reduction on microbial
flora. Although generally confirming the
above findings, the results were more het-
erogeneous due to different methodologies
and the actual complexityofhuman lifestyle
as compared with experimental animal
models, where all potential confounding
factors, including the frequency and com-
position of meals, can be precisely con-
trolled. For these reasons, a definite causal
relationship between gut microbiota and
the development of obesity remains to be
demonstrated in humans (16–21).
Mechanisms linking gut microbiota
to obesity, IR, and type 2 diabetes
Beside an increased energy harvest from
the diet, further mechanisms linking gut
microbiota to obesity have been subse-
quently proposed, including chronic low-
grade endotoxinemia, regulation of
tissutal biologically active fatty acid com-
position and modulation of gut-derived
peptide secretion.
Chronic inflammation induced by low-
grade endotoxinemia. Metabolic path-
ways are functionally integrated with
immune responses, and the relevance of
the innate immune system for the patho-
genesis of metabolic disorders is increas-
ingly recognized, e.g., in mice fed a high-
fat diet, the activation of liver resident
macrophages Kupffer cells promotes he-
patic IR and glucose intolerance. The se-
lective depletion of these cells, without
affecting adipose tissue macrophages, re-
stores hepatic insulin sensitivity and im-
proves whole-body and hepatic fat
accumulation along with glucose metab-
olism (22,23).
Recent work has shown that gut bac-
teria can initiate the inflammatory state of
obesity and IR through the activity of li-
popolysaccharide (LPS), a component of
the gram-negative bacterial cell walls,
which can trigger the inflammatory pro-
cess by binding to the CD14 toll-like re-
ceptor-4 (TLR-4) complex at the surface
of innate immune cells. The relevance of
the TLR-4 pathways for metabolic disease
was confirmed by the finding that the de-
letion of TLR-4 prevented the high-fat
diet–induced insulin resistance (24).
Cani et al. (25) elegantly demon-
strated that after 4 weeks of high-fat feed-
ing, mice exhibited an obese phenotype
accompanied by a change in gut micro-
biota composition (the reduction of Bi-
fidobacteria and Eubacteria spp.) and a
two- to threefold increase in circulating
LPS levels, which they called “metabolic
endotoxemia” since LPS plasma concen-
trations were much lower than those
observed during septic shock.Whenmet-
abolic endotoxemia was reproduced by
subcutaneous infusion of LPS, animals
developed the same metabolic abnormal-
ities induced by the high-fat diet, while
LPS receptor KO (CD14KO) mice were
resistant to the effects of both high-fat diet
and LPS infusion. Moreover, CD14KO
mice were hypersensitive to insulin even
when they were fed a normal diet, sug-
gesting that CD14 may modulate insulin
sensitivity in physiological conditions. In
a subsequent experiment (26), changes in
gut microbiota composition induced by
antibiotic treatment reduced metabolic
endotoxemia and the cecal content of
LPS, closely correlating with an improve-
ment in the obese phenotype in both
high-fat-fed and ob/ob mice (supplemen-
tary Table 1).
The role of LPS in triggering systemic
inflammation was subsequently evalu-
ated in healthy human subjects. Anderson
et al. (27) found a similar grade endotox-
emia increased adipose tumor necrosis
factor (TNF)- and interleukin (IL)-6
concentrations and promoted IR, and a
high-fat, high-carbohydrate meal in-
duced a significant postprandial plasma
LPS elevation, accompanied by an in-
creased mononuclear cell expression of
TLR-4, nuclear factor-B (NF-B), and
suppressor of cytokine signaling-3
(SOCS-3), an adipokine involved in IR.
These increases were totally absent after
an American Heart Association (AHA)
meal rich in fiber and fruit (28).
Taken together, these data support
the concept that endotoxinemia may play
a key role in the pathogenesis of obesity-
associated inflammatory state and that
food ingestion affects plasma endotoxin
levels.
Different nutrients have different pro-
endotoxinemic potentials. The knowl-
edge of the impact of different nutrients
on microbial LPS production or on intes-
tinal LPS absorption could have relevant
therapeutic implications. The finding that
high-fat feeding reduced the expression
of epithelial tight junction proteins occlu-
din and ZO-1, leading to increased intes-
tinal permeability and LPS levels, suggests
Musso, Gambino, and Cassader
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intestinal fat absorption and secretion
may have a predominant role in LPS entry
into the portal blood (47). Consistently, a
high-fat diet induced a higher increase in
plasma LPS compared with an isocaloric
high-carbohydrate diet in mice (29). The
ability of fat to induce higher endotoxin
levels seems confirmed in recent human
studies. In a sample of 201 healthy men,
circulating LPS concentrations positively
correlated with 3-day total energy and fat,
but not with other nutrient intake (29). In
healthy subjects, a high-fat meal acutely
increases plasma endotoxemia to concen-
trations that are sufficient to activate cul-
tured human aortic endothelial cells
through the release of soluble TNF-
from monocytes (30). Deopurkar et al.
(31) compared the effects of an isocaloric
meal rich in glucose, saturated fat
(cream), or orange juice on plasma endo-
toxin, oxidative, and inflammatory mark-
ers in healthy subjects, and while the
expression of NF-B, SOCS3, TNF-,
and IL-1 increased significantly follow-
ing glucose and cream intake, plasma LPS
concentrations and TLR-4 expression in-
creased only after cream intake. Orange
juice did not change any of the indexes
measured, and, when added to a high-fat,
high-carbohydrate meal, it prevented
postprandial increase in plasma endo-
toxin, TLR-4, and related inflammatory
markers (31,32) (supplementary Table 1).
Another dietary pattern that has been
linked to both metabolic disorders and
endotoxinemia is excessive fructose in-
take. Mice consuming high-fructose solu-
tion for 8 weeks showed a 27-fold
increase in portal endotoxin levels, cou-
pled with a significant increase in plasma
inflammatory cytokines, hepatic steato-
sis, and IR, comparedwithwater controls.
These alterations, except increased portal
endotoxin levels, were markedly blunted
in fructose-fed TLR-4–mutant mice, fur-
ther confirming the LPS-TLR-4 axis may
mediate the deleterious metabolic effects
of excessive fructose intake (33).
Collectively, these data suggest dif-
ferent nutrients have different abilities
to induce an endotoxinemic and inflam-
matory response with fat and possibly
fructose having the greatest potential.
Plasma endotoxin increase may derive
from enhanced LPS production by micro-
biota or from increased intestinal LPS ab-
sorption. Unfortunately, little is known
about mechanisms regulating LPS ab-
sorption. Ghoshal et al. (34) showed that
endotoxin is actively secreted into the
blood along with the formation and secre-
tion of chylomicrons in animals and cul-
tured enterocytes and is not just
translocated due to the breakdown of the
intestinal barrier, and that inhibiting chy-
lomicron formation blocked LPS secre-
tion. These findings suggest that the
inhibition of chilomicron secretion may
effectively reduce metabolic endotoxine-
mia and may ultimately benefit obesity-
associated metabolic disorders, even in
the absence of overt hyperlipidemia.
Other modulators of gut microbiota
composition. Growing evidence sug-
gests factors other than dietary habits can
modulate gut microflora and that the 1st
years of life have a crucial impact on the
individual’s gut microbiota composition.
In a prospective study (35), children be-
coming overweight by 7 years of age had
lower levels of Bifidobacteria and higher
levels of Staphylococcus aureus during the
1st year of life than infants maintaining a
healthy weight. Another study (17) found
that the response of overweight adoles-
cents to a diet and exercise weight-loss
program was dependent on the initial mi-
crobiota prior to the treatment.
While not taking into account con-
founders such as various nutrient intake,
these studies suggest the knowledge of
factors modulating gut microbiota com-
position early in life may have therapeutic
or preventive implications for adult
obesity.
The fetus is sterile in uterus and is
colonized by microbes during its passage
through the birth canal. Immediately after
birth, the baby is exposed to several envi-
ronmental sources of bacteria (e.g., skin,
mouth, mother’s milk). This initial micro-
biota changes dynamically during the first
months of life, owing to the continuous
exposure to different environmental bac-
teria. Gut microbiota has fully matured
by the first 1–2 years of life, coincidingwith
the weaning from the high-fat milk diet
to the solid high-carbohydrate diet,
and thereafter remains substantially con-
stant throughout the individual’s life and
fluctuates around a core of stable colonizers
(36,37). Results from the KOALA (Kind,
Ouders en gezondheid: Aandacht voor
Leefstijl en Aanleg) Birth Cohort and
other studies have suggested the mode of
delivery, type of infant feeding, hospital-
ization, prematurity, and antibiotic use
determine the gut microbial composition
during infancy (38–40). During a natural
birth, infants are rapidly colonized by mi-
crobes from the mother’s birth canal and
feces, while babies delivered by cesarean
section are colonized by environmental
microbes from their mother, the air, and
transferred by the nursing staff. As a re-
sult, infants delivered by cesarean section
have fewer intestinal Bifidobacteria and
Bacteroides spp. (two species shown to be
protective against obesity) and are more
often colonized by C. difficile in compari-
son with vaginally delivered infants.
Formula-fed infants are more often
colonized with Enterobacteriaceae spp., C.
difficile, Bacteroides spp., and Streptococcus
spp. compared with breast-fed infants
who are predominantly colonized by
Staphylococcus spp., Streptococcus spp.,
Lacobacilllus spp., and Bifidobacterium
spp. Whether different gut microbe colo-
nization explains the different propensity
for obesity from different infant feeding
requires further studies with careful pro-
spective monitoring of gut flora and life-
style habits.
The pervasive impact of antibiotic use
on gut microbes is also increasingly rec-
ognized, e.g., a 5-day course of oral anti-
biotics modifies human gut microbiota
for up to 4 weeks before it tends to revert
to its original composition, and some
communities fail to recover within 6
months (41). Consistently, the use of an-
tibiotics in infants is associated with the
decreased number of the antiobesogenic
Bifidobacteria and Bacteroides, and after
antibiotic treatment there is a slow re-
growth of Bifidobacteria, whereas Bacte-
roides spp. are not usually reestablished
(38).
Collectively, these findings highlight
the importance of nondietary factors in
determining the composition of gut
microflora.
Regulation of adipose tissue and
liver fatty acid composition by gut
microbes
Gutmicrobiota can also affect hostmetab-
olism and inflammatory state bymodulat-
ing the tissue fatty acid composition:
mammalian intestinal Lactobacilli and Bi-
fidobacteria can synthesize from free lino-
leic acid bioactive isomers of conjugated
linoleic acid, which have antidiabetic, an-
ti-atherosclerotic, immunomodulatory,
and anti-obesity properties (42). The sup-
plementation of Bifidobacterium breve
and linoleic acid to different mammalian
species resulted in a two- to threefold
higher intestinal, hepatic, and adipose tis-
sue content of cis-9, trans-11 conjugated
linoleic acid, eicosapentaenoic acid, and
docosahexaenoic acid, concomitantly
with a reduced proinflammatory cyto-
kines TNF-, IL-6, and interferon- ex-
Gut microbiota and obesity
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pression, than the linoleic acid-alone
supplemented diet (43) (supplementary
Table 1).
Gut microbiota modulates
gut-derived peptide secretion
PYY. Gut microbiota synthesizes a large
amount of glycoside hydrolases that
break down complex plant polysaccha-
rides tomonosaccharides and short-chain
fatty acids, mainly acetate, propionate,
and butyrate. Beside representing an im-
portant source of energy for de novo lipo-
genesis, these short-chain fatty acids are
ligands for twoG-protein–coupled recep-
tors, Gpr41 and Gpr43, of gut enteroen-
docrine cells (44). Upon ligand binding,
these G-protein–coupled receptors stim-
ulate secretion of PYY, which inhibits gut
motility and slows intestinal transit
thereby enhancing nutrient absorption.
Consistent with these properties, conven-
tionally raised Gpr41-deficient mice or
germ-free Gpr41-deficient mice colonized
with Bacteroidetes theatiotaomicron and
Methanobrevibacter smithii (two common
commensals of human distal gut) were
significantly leaner than wild-type litter-
mates, whereas there were no genotype-
related differences in germ-free mice.
Gpr41 deficiency was associated with de-
creased expression of PYY, faster intesti-
nal transit rate, and reduced harvest of
energy from the diet (44) (supplementary
Table 1).
GLP-1 secretion. Gut microbiota fer-
mentation of prebiotics promoted L-cell
differentiation in the proximal colon of
rats and increased glucagon-like peptide
(GLP)-1 response to a meal in healthy hu-
mans (45,46). Ob/ob mice treated with
prebiotic carbohydrates had altered gut
microbiomas and increased circulating
GLP-1 and GLP-2 (47). Further support-
ing the relevance of GLP-1 in mediating
prebiotic action, genetic or pharmacolog-
ical deletion of GLP-1 prevented the ben-
eficial effects of prebiotics on weight gain,
glucose metabolism, and inflammatory
pathway activation (48,49).
GLP-2 secretion. Recent experimental
data suggest gut microbiota may modu-
late gut barrier integrity and endotoxine-
mia through GLP-2, a 33-amino acid
peptide with known intestinotrophic
properties, which is cosecreted with
GLP-1 by enteroendocrine L-cells.
Cani et al. (47) assessed the effect of
the prebiotic fermentable oligofructose
on gut microbiota composition, intestinal
permeability, and hepatic and systemic
inflammation in ob/ob mice. Compared
with the carbohydrate-alone diet, the pre-
biotic  carbohydrate diet increased the
intestinal proportion of Lactobacilli and
Bifidobacteria, preserved tight junction
integrity and intestinal barrier function,
and lowered endotoxinemia and systemic
and hepatic cytokines and oxidative
stress. These effects were associated with
an increased intestinal GLP-2 production,
were abolished by the pretreatment with a
GLP-2 antagonist, and were mimicked by
the administration of a GLP-2 agonist
(47), thus suggesting GLP-2 may mediate
the benefits of prebiotics.
Gut microbiota manipulation:
human trials
Following the encouraging results in ani-
mals (50,51), the effects of manipulating
enteric flora by probiotics (live bacteria
given in oral quantities that allow for col-
onization of the colon) or prebiotics (non-
digestible oligosaccharides like insulin
and oligofructose that are fermented by
colonic microbiota and enhance the
growth of beneficial commensal organ-
isms like Bifidobacterium and Lactobacillus
spp.) have been evaluated in several con-
trolled trials (supplementary Table 2).
The randomized controlled trials (RCTs)
did not exceed 6 months’ duration, were
mostly relatively small-sized (50 partic-
ipants), and evaluated surrogate markers
rather than clinical end points, which fur-
ther substantiated the mechanisms of ac-
tion of pre/probiotics formerly elucidated
in animals, e.g., increased satiety and re-
duced caloric intake by prebiotics, en-
hanced GLP-1 and PYY responses, and
reduced glucose excursions and inflam-
matory responses postprandia l ly
(52–54).
The three largest RCTs evaluated the
effect of probiotics on pregnancy out-
comes and perinatal growth patterns. The
impact of perinatal probiotic administra-
tion on the development of overweight
and obesity was assessed in a follow-up
study from birth to 10 years of age (55),
e.g., 159 pregnant women were random-
ized to receive probiotics (Lactobacillus
rhamnosus) or placebo from 4 weeks prior
to delivery through 6 months after deliv-
ery. The perinatal probiotic intervention
was safe and moderated weight gain dur-
ing the first 1–2 years of life, but did not
affect the second phase of excessive
weight gain starting after 24–48 months
of age. The intervention also showed a
trend to reduce the birth weight-adjusted
mean BMI at 4 years of age.
Two RCTs assessed the effect of ma-
ternal probiotic-supplemented dietary
counseling on pregnancy outcome, glu-
cose regulation, and perinatal growth,
e.g., 256 women were randomized in the
1st trimester of pregnancy to receive nu-
tritional counseling or as control subjects;
the dietary intervention groupwas further
double-blindly randomized to receive
probiotics (Lactobacillus rhamnosus and
Bifidobacterium lactis) or placebo (diet/
placebo), while the control group re-
ceived placebo (control/placebo) (56,57).
Overall, probiotic supplementation was
safe with blood glucose concentrations
and homeostasis model assessment index
during pregnancy and over the 12-month
postpartum period the lowest in the diet/
probiotics group, which also had a re-
duced incidence of gestational diabetes
mellitus. No significant differences in pre-
natal or postnatal growth rates among the
study groups were detected, but dietary
intervention diminished the risk of larger
birth size in affected cases.
Conclusions
Numerous animal models consistently
demonstrated that gut microbiota can
modulate host energy homeostasis and
adiposity through different mechanisms,
e.g., energy harvest from the diet, LPS-
induced chronic inflammation, modula-
tion of tissue fatty acid composition, and
gut-derived peptide secretion. Although
extensive experimental data suggested
gut microbiota manipulation can benefi-
cially affect host adiposity and glucose
metabolism, a causal relationship be-
tween gutmicrobes and obesity still needs
to be proven in humans, in whom current
data suggest an association between gut
microbiota, Western diet, and obesity. In
the only follow-up study (35) prospec-
tively connecting gut microbiota to the
development of obesity, other factors, in-
cluding dietary habits, were not assessed,
making causal inference uncertain. The
assessment of pro/prebiotic efficacy in
free-living humans is far more complex
than under standardized experimental
conditions because different confounding
factors, including antibiotic use, back-
ground diet and physical activity, endo-
toxin content of ingested food, and even
meal frequency (58), may affect gut mi-
crobiota, energy balance, and ultimately
body weight. Understanding these factors
may allow researchers to design future tri-
als and better understand the relative im-
pact of pre/probiotics on the treatment of
obesity, which is a complex disease deriv-
ing from the interaction of largely un-
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known mul t ip l e gene t i c and
environmental factors. The ongoing dou-
ble-blind, randomized, controlled trial,
FATLOSE, is assessing the effect of
healthy donor feces transplantation on
glucose homeostasis and intestinal in-
flammation in subjects with metabolic
syndrome andwill hopefully help address
these issues. Furthermore, the long-term
safety of gut microbiota manipulation
needs assessment. We are used, in fact, to
consider probiotics a safer alternative or a
complement to drugs, but the impact of
prolonged perturbation in gut microbial
ecology is unknown, as currently only
one RCT specifically assessed the safety of
probiotic supplementation for as long as 6
months (59).
Future research should also move be-
yond profiling human gut microbial
species and focus on the functional prop-
erties ensuring health benefits for the
host. Toward this aim, it will be essential
to elucidate the complex mechanisms of
action of pre/probiotics, which are only
lately being unraveled. These include the
production of direct antimicrobial sub-
stances (bacteriocins); the competition
for the same biological niche and preven-
tion of replication of other communities
(colonization resistance); the stimulation
of production of antibacterial substances,
including mucins by epithelial cells and
defensins by crypt Paneth cells; the mod-
ulation of the epithelial cell proinflamma-
tory transcription factor NF-B; and the
stimulation of mucosal B-cell and T-cell
immunity to produce secretory immuno-
globulin A, proinflammatory (i.e., IL-12),
or anti-inflammatory (i.e., IL-10) cyto-
kines (60). Importantly, most effects are
strain-specific and varying probiotic
strains can exert different and even oppo-
site anti- or proinflammatory actions.
These data emphasize the need for a
deeper knowledge of molecular mecha-
nisms underlying microbe-microbe and
microbe-host interactions to tailor a more
selective approach targeting the individ-
ual needs.
While awaiting well designed RCTs
with clinical end points, the importance
of a “healthy” lifestyle in its broader
sense—including breast lactation, a
healthy diet, avoiding excessive fat, ap-
propriate antibiotic use—cannot be over-
emphasized andmay ensure a friendly gut
microbiota, positively affecting metabolic
outcomes. A concept that can be drawn
from available studies is that the nutrient
value of food is a relative and not an ab-
solute term that can be influenced by our
microbiome metabolic activity. Con-
versely, our food choices may imprint
into inner intestinal metabolome by af-
fecting the structure and activity of the gut
microbiota. This metabolic imprinting
starts at an early stage of life and met-
agenomic studies could allow researchers
to obtain a deeper understanding of the
nutritional needs of humans and yield
microbiome-based biomarkers for iden-
tifying those at risk for obesity. The un-
derstanding of factors modulating gut mi-
crobiota assembly early in life may have
preventive implications for adult obesity.
Under an evolutionary perspective, the
obesity epidemic can be viewed as an ex-
tension of the hygiene hypothesis: the
data presented suggest that improved
sanitation and living conditions, overzeal-
ous antimicrobial therapy, and Western-
ized dietary patterns in developed
countries may predispose to metabolic
diseases just as improved hygiene in-
creased the susceptibility to allergic and
autoimmune diseases, and that a deviant
gut microbiota may mediate these
associations.
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